Fasting serum adiponectin level inversely correlates with metabolic syndrome in peritoneal dialysis patients

Blood Purification

Volumn 30, Issue 1, 2010, Pages 1-7

  Wang, Chih Hsien ^a,b   Wang, Ji Hung ^b   Lee, Chung Jen ^c   Fang, Te Chao ^a,b   Liou, Hung Hsiang ^d   Hsu, Bang Gee ^a,b  

^a TZU CHI UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c TZU CHI COLLEGE OF TECHNOLOGY   (Taiwan)

^d Hsin Jen Hospital   (Taiwan)

Author keywords

Adiponectin; Metabolic syndrome; Peritoneal dialysis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SERUM ALBUMIN; STATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; DIET RESTRICTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PERITONEAL DIALYSIS; PRIORITY JOURNAL; WAIST CIRCUMFERENCE;

ADIPONECTIN; AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FASTING; FEMALE; HUMANS; LINEAR MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PERITONEAL DIALYSIS; PREDICTIVE VALUE OF TESTS;

EID: 77952302615     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314647     Document Type: Article

References (40)

1. Oh DK, Ciaraldi T, Henry RR: Adiponectin in health and disease. Diabetes Obes Metab 2007; 9: 282-289.
2. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Novel modulator for endothelial adhesion molecules: adipocyte- derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476.
3. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
4. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737.
5. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A: Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 2004; 27: 2450-2457.
6. Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB: Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4542-4548.
7. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y: Adiponectin, metabolic risk factors, and cardiovascular events among patients with endstage renal disease. J Am Soc Nephrol 2002; 13: 134-141.
8. Rao M, Li L, Tighiouart H, Jaber BL, Pereira BJ, Balakrishnan VS; HEMO Study Group: Plasma adiponectin levels and clinical outcomes among haemodialysis patients. Nephrol Dial Transplant 2008; 23: 2619-2628.
9. Tsao YT, Hsu YJ, Chu NF, Lai CH, Chiu JS, Lin SH: Association of plasma adiponectin and cardiovascular risk profiles in nondiabetic uremic patients on peritoneal dialysis. J Nephrol 2008; 21: 744-752.
10. Yu ZZ, Ni ZH, Gu LY, Lin AW, Fang W, Yao Q, Lindholm B, Qian JQ: Adiponectin is related to carotid artery plaque and a predictor of cardiovascular outcome in a cohort of non-diabetic peritoneal dialysis patients. Blood Purif 2008; 26: 386-393.
11. Isomaa B, Almgren P, Tuomi T, Forsé B, Lahti K, Nissé M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
12. Peralta CA, Kurella M, Lo JC, Chertow GM: The metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens 2006; 15: 361-365.
13. Yang SY, Chiang CK, Hsu SP, Peng YS, Pai MF, Ho TI, Hung KY, Wu KD: Metabolic syndrome predicts hospitalization in hemodialysis patients: a prospective Asian cohort study. Blood Purif 2007; 25: 252-259.
14. Wang AY: Cardiovascular risk factors in peritoneal dialysis patients revisited. Perit Dial Int 2007; 27(suppl 2):S223-S227.
15. Mohan V, Deepa R, Pradeepa R, Vimaleswaran KS, Mohan A, Velmurugan K, Radha V: Association of low adiponectin levels with the metabolic syndrome - the Chennai Urban Rural Epidemiology Study (CURES-4). Metabolism 2005; 54: 476-481.
16. Gilardini L, McTernan PG, Girola A, da Silva NF, Alberti L, Kumar S, Invitti C: Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents. Atherosclerosis 2006; 189: 401-407.
17. Wang J, Li H, Franco OH, Yu Z, Liu Y, Lin X: Adiponectin and metabolic syndrome in middle-aged and elderly Chinese. Obesity 2008; 16: 172-178.
18. WHO Expert Consultation: Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-163.
19. Lee CC, Lee RP, Subeq YM, Wang CH, Fang TC, Hsu BG: Fasting serum total ghrelin level inversely correlates with metabolic syndrome in hemodialysis patients. Arch Med Res 2008; 39: 785-790.
20. Alberti KG, Zimmet PZ, Shaw J: Metabolic syndrome - a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480.
21. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
22. Davies SJ, Phillips L, Naish PF, Russell GI: Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12: 1046-1051.
23. Scott CL: Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol 2003; 92: 35i-42i.
24. Jiang N, Qian J, Lin A, Lindholm B, Axelsson J, Yao Q: Initiation of glucose-based peritoneal dialysis is associated with increased prevalence of metabolic syndrome in nondiabetic patients with end-stage renal disease. Blood Purif 2008; 26: 423-428.
25. Lee CJ, Subeq YM, Wang CH, Lee RP, Fang TC, Hsu BG: Fasting serum ghrelin level is associated with metabolic syndrome in peritoneal dialysis patients. Perit Dial Int 2008; 28(suppl 3):S196-S200.
26. Chen HY, Kao TW, Huang JW, Chu TS, Wu KD: Correlation of metabolic syndrome with residual renal function, solute transport rate and peritoneal solute clearance in chronic peritoneal dialysis patients. Blood Purif 2008; 26: 138-144.
27. Ducloux D, Bresson-Vautrin C, Kribs M, Abdelfatah A, Chalopin JM: C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 2002; 62: 1417-1422.
28. Wang AY: Prognostic value of C-reactive protein for heart disease in dialysis patients. Curr Opin Investig Drugs 2005; 6: 879-886.
29. Rabe K, Lehrke M, Parhofer KG, Broedl UC: Adipokines and insulin resistance. Mol Med 2008; 14: 741-751.
30. Huang JW, Yen CJ, Chiang HW, Hung KY, Tsai TJ, Wu KD: Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. Am J Kidney Dis 2004; 43: 1047-1055.
31. Yun JE, Sull JW, Lee HY, Park E, Kim S, Jo J, Lee SJ, Kim SY, Choi YJ, Jee SH, Huh KB: Serum adiponectin as a useful marker for metabolic syndrome in type 2 diabetic patients. Diabetes Metab Res Rev 2009; 25: 259-265.
32. Hazel M, Cooksey RC, Jones D, Parker G, Neidigh JL, Witherbee B, Gulve EA, Mc- Clain DA: Activation of the hexosamine signaling pathway in adipose tissue results in decreased serum adiponectin and skeletal muscle insulin resistance. Endocrinology 2004; 145: 2118-2124.
33. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
34. Haluzík M, ParíkováJ, Haluzík MM: Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiol Res 2004; 53: 123-129.
35. Kantartzis K, Rittig K, Balletshofer B, Machann J, Schick F, Porubska K, Fritsche A, Híng HU, Stefan N: The relationships of plasma adiponectin with a favorable lipid profile, decreased inflammation, and less ectopic fat accumulation depend on adiposity. Clin Chem 2006; 52: 1934-1942.
36. Yilmaz MI, Sonmez A, Caglar K, Gok DE, Eyileten T, Yenicesu M, Acikel C, Bingol N, Kilic S, Oguz Y, Vural A: Peroxisome proliferator- activated receptor gamma (PPARgamma) agonist increases plasma adiponectin levels in type 2 diabetic patients with proteinuria. Endocrine 2004; 25: 207-214.
37. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K: Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81.
38. Yenicesu M, Yilmaz MI, Caglar K, Sonmez A, Eyileten T, Acikel C, Kilic S, Bingol N, Bingol S, Vural A: Blockade of the renin-angiotensin system increases plasma adiponectin levels in type-2 diabetic patients with proteinuria. Nephron Clin Pract 2005; 99: c115-c121.
39. Koh KK, Quon MJ, Han SH, Ahn JY, Jin DK, Kim HS, Kim DS, Shin EK: Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005; 45: 1088-1093.
40. Furuya R, Odamaki M, Kumagai H, Hishida A: Impact of angiotensin II receptor blocker on plasma levels of adiponectin and advanced oxidation protein products in peritoneal dialysis patients. Blood Purif 2006; 24: 445-450.